ArticlePloS one2025
Average annual costs of Rheumatoid Arthritis estimated by inverse probability weighting and their influence factors: A cross-sectional study based on Chinese Registry of Rheumatoid arthritis (CREDIT) Cohort.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Frailty Transition and Risk of New-Onset Arthritis Among Adults Aged 45 Years and Older: A Longitudinal Analysis of CHARLS.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo date, the evidences of economic burden for the RA individual in the real-world clinical practice were still limited in China. This study aimed to estimate average annual costs of rheumatoid arthritis (RA) patients using inverse probability weighting (IPW) and their influence factors.
methodsA multicenter, cross-sectional study was conducted and the RA patients who met inclusion criteria on CREDIT cohort were invited to participate the survey. After they signed the informed confirm form, the information of outpatient and inpatient expenditures in the past year were collected through online questionnaires. Medical records were retrieved from the Chinese Rheumatology Information System (CRIS). Propensity scores for sample using the Generalized Boosted Model (GBM) method were used to calculate IPW, so that we produced the weighted population similar to the target of RA patients on CREDIT. Bootstrap methods were used to estimate average costs and 95% confidence intervals with 1,000 samples. Indirect costs were estimated using the human capital approach. Weighted multivariate regression identified factors influencing average annual costs.
resultsIn this study, a total of 18,507 patients from the CREDIT database met the recruitment criteria. Among them, 1,293 patients from 152 hospitals across 29 provinces in China completed the questionnaire and were included in our analysis. The average annual total costs per patient by the Bootstrap method on the weighted population was about 41,971 CNY (Bootstrap 95%CI: 37,107-47,046 CNY), in which more than 75% were the direct costs. Moreover, in the direct costs, the medical costs accounted for nearly 89% and even half of them (approximately 59.7%) was medication expense. The moderate or high disease activity status, hospitalization in last year, history of comorbidity, the treatment of biologics or glucocorticoids were also found to substantially increase average annual costs of RA in our study.
conclusionsThis study provided reliable insight into evaluating the economic burden of RA for the individuals and their families in the real-world clinical practice of China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.